Health and Healthcare
Johnson & Johnson Accelerates Its COVID-19 Vaccine Hopes
Published:
Johnson & Johnson (NYSE: JNJ) has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19. Shares got a mild boost on Wednesday from the news.
Specifically, Johnson & Johnson is pushing its Phase 1/2a clinical trial of Ad26.COV2-S, which is its investigational SARS-CoV-2 vaccine.
The company noted that it would accelerate the development of this vaccine based on preclinical data and its talks with regulatory bodies.
The trial will be double-blind and placebo-controlled, investigating the safety, response to vaccination and immune response of the vaccine in adults between the ages of 18 to 55 and adults aged 65 and over. It will take place in the United States and Belgium.
Currently, Johnson & Johnson is interacting with the National Institutes of Allergy and Infectious Diseases in an effort to start its Phase 3 trial ahead of schedule. This is pending the results of the Phase 1 trial and regulatory approval.
Johnson & Johnson began crafting this vaccine in January.
Paul Stoffels, chief scientific officer, commented:
Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
Johnson & Johnson stock traded up more than 1% at $147.92 on Wednesday, in a 52-week range of $109.16 to $157.00. The consensus price target is $164.17.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
